Sanofi (NASDAQ:SNY) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Sanofi from “Buy” to “Hold.” The broader analyst consensus is also “Hold,” with an average price target of $49.50.
• Sanofi shares opened at $43.46, up 1.3%, with a market capitalization of approximately $105.37 billion. The stock has traded between $40.89 and $52.68 over the past 12 months.
• Institutional investors and hedge funds own 14.03% of Sanofi, with several firms increasing their positions or initiating new stakes in the company.

Sanofi (NASDAQ:SNY - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Sunday.

A number of other equities analysts have also weighed in on SNY. Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. Argus raised Sanofi to a "strong-buy" rating in a research note on Monday, April 27th. Weiss Ratings lowered Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, August 3rd. BNP Paribas Exane cut shares of Sanofi from an "outperform" rating to a "neutral" rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Finally, Citigroup restated a "neutral" rating on shares of Sanofi in a research report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $49.50.

Sanofi Stock Up 1.3%

SNY stock opened at $43.46 on Friday. The company has a market cap of $105.37 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 1.08 and a beta of 0.35. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The firm has a 50-day moving average of $43.31 and a two-hundred day moving average of $45.06.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently modified their holdings of the company. Benson Investment Management Company Inc. acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $5,424,000. Assetmark Inc. lifted its holdings in Sanofi by 24.2% during the 4th quarter. Assetmark Inc. now owns 443,668 shares of the company's stock worth $21,500,000 after buying an additional 86,496 shares in the last quarter. QRG Capital Management Inc. boosted its position in Sanofi by 18.6% in the 4th quarter. QRG Capital Management Inc. now owns 111,465 shares of the company's stock valued at $5,402,000 after buying an additional 17,511 shares during the period. Evergreen Capital Management LLC grew its stake in shares of Sanofi by 37.1% in the fourth quarter. Evergreen Capital Management LLC now owns 45,636 shares of the company's stock worth $2,212,000 after acquiring an additional 12,347 shares in the last quarter. Finally, AMG National Trust Bank purchased a new stake in shares of Sanofi during the first quarter worth $2,719,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source